COMPANY
Immune-Onc Therapeutics, Inc.
Timeline
- Trial start 1: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors source ↗
- Trial start Phase 1: Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors source ↗
- Trial start Phase 1: First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors source ↗
- Trial start Phase 1: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04372433 | IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML | Phase 1 | Completed | Sep 14, 2020 | Jan 31, 2025 (actual) |
| NCT05309187 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | Phase 1 | Completed | Apr 11, 2022 | Mar 29, 2024 (actual) |
| NCT05054348 | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | Phase 1 | Completed | Sep 30, 2021 | Apr 29, 2024 (actual) |
| NCT05508100 | Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors | 1 | Completed | Sep 9, 2022 | Apr 30, 2024 (actual) |
NIH awards 2
- NIH award 5R44CA250543-02 FY2021: $1,070,000 awarded for that fiscal year; activity R44 (SBIR); PI LIAO, CHARLENE; recipient as written: IMMUNE-ONC THERAPEUTICS, INC., PALO ALTO, CA. Non-clinical Combination Pharmaco source ↗
- NIH award 1R44CA250543-01A1 FY2020: $1,070,000 awarded for that fiscal year; activity R44 (SBIR); PI LIAO, CHARLENE; recipient as written: IMMUNE-ONC THERAPEUTICS, INC., PALO ALTO, CA. Non-clinical Combination Pharma source ↗